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ReactionAbstract Objectives: To discuss the effect of certain factors on the occurrence of Adverse Drug
Reactions (ADRs).
Data Sources: A systematic review of the literature in the period between 1991 and 2012 was
made based on PubMed, the Cochrane database of systematic reviews, EMBASE and IDIS. Key
words used were: medication error, adverse drug reaction, iatrogenic disease factors, ambulatory
care, primary health care, side effects and treatment hazards.
Summary: Many factors play a crucial role in the occurrence of ADRs, some of these are patient
related, drug related or socially related factors. Age for instance has a very critical impact on the
occurrence of ADRs, both very young and very old patients are more vulnerable to these reactions
than other age groups. Alcohol intake also has a crucial impact on ADRs. Other factors are gender,
race, pregnancy, breast feeding, kidney problems, liver function, drug dose and frequency and many
other factors. The effect of these factors on ADRs is well documented in the medical literature. Tak-
ing these factors into consideration during medical evaluation enables medical practitioners to
choose the best drug regimen.
Conclusion: Many factors affect the occurrence of ADRs. Some of these factors can be changed
like smoking or alcohol intake others cannot be changed like age, presence of other diseases or
genetic factors. Understanding the different effects of these factors on ADRs enables healthcare
professionals to choose the most appropriate medication for that particular patient. It also helps
the healthcare professionals to give the best advice to patients. Pharmacogenomics is the most
recent science which emphasizes the genetic predisposition of ADRs. This innovative science pro-
vides a new perspective in dealing with the decision making process of drug selection.
ª 2013 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
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Safety issues arise whenever medical choices have to be made
(Bauer, 2008). ADRs can occur in all settings where healthcare
is provided. Most of the current evidence comes from hospitals
because the risks associated with hospital treatment are higher
(Yurdaguel et al., 2008). Many such events occur in other
healthcare settings such as consulting rooms, nursing homes,
pharmacies, community clinics and patients’ homes (Steven
et al., 2008). While the drug manufacturing process has been
revolutionized by modern techniques, drug safety assessment
stays behind and is still reliant on technologies that have been
used for several decades (Powley et al., 2009). Current concep-
tual thinking on the safety of patients places the prime respon-
sibility for ADRs on deﬁciencies in system design,
organization and operation – rather than on individual practi-
tioners or products. Berwick and Leape (1999) recommended
that checks and quality assurance should be built into the
use system, rather than assuming that all will be well. By the
time a drug is marketed, only about 1500 patients may have
been exposed to the drug. Thus, only those ADRs occurring
at a frequency of greater than 1 in 500 will have been identiﬁed
at the time of licensing (Andrade et al., 2007). Pirmohamed
et al., 1998 suggested that the assessment of ADRs therefore
is likely to represent an important aspect of drug therapy.
Bates et al., 2003 showed that the overall rate of ADRs is esti-
mated to be 6.5 per 100 admissions; 28% of these reactions are
preventable. Once marketed, a drug loses the scientiﬁc envi-
ronment of clinical trials and is legally set free for consumption
by the public (Russell et al., 1992). At this point, most drugs
will only have been tested for short-term safety on a limited
number of previously deﬁned and selected individuals.
ADR is deﬁned as a response to a drug which is noxious
and unintended, and which occurs at doses normally used inman for the prophylaxis, diagnosis, or therapy of disease, or
for the modiﬁcation of physiological function (WHO, 1973).
It is also deﬁned as an undesirable effect, reasonably associ-
ated with the use of the drug that may occur as a part of the
pharmacological action of a drug or may be unpredictable in
its occurrence (Edwards and Aronson, 2000).
1.1. Magnitude of ADRs
ADRs are one of the leading causes of morbidity and mortality
in healthcare. The Institute of Medicine, in the United States
(US) (2000) reported that between 44,000 and 98,000 deaths
occur annually from medical errors. Of this total, an estimated
7000 deaths occur due to ADRs. Analyzing 39 studies of the
American pharmaceutical system over four decades found that
in 1994, 106,000 people died as a result of ADRs. More than
2 million suffered serious side effects (Pomeranz and Bruce,
1998). These ﬁgures showed that there was a trend of increas-
ing death and injury from ADRs. That would make ADRs the
fourth leading cause of death in the US behind heart disease,
cancer and strokes (Jemal et al., 2005). In another survey con-
ducted by the American Society of Health-System Pharma-
cists, Byrne et al. (2006) found that 85% of patients who
responded to the survey expressed concerns about at least
one drug-related issue, such as receiving interacting drugs, hav-
ing harmful adverse effects from a drug, or receiving the wrong
drug. ADRs are a signiﬁcant public health problem in the
world. Not only do ADRs cause death and injury but they also
affect the length of stay in hospitals which in turn leads to in-
creased healthcare costs and decreased patient productivity.
Moura et al. (2009) determined the frequency of ADRs in
intensive care units and evaluated their effect on the length
of stay and found out that each ADR presented by the patient
was related to an increase of 2.38 days in the ICU. In research
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sessed. It was found that, a total of 1225 admissions were re-
lated to an ADR, giving a prevalence of 6.5%. The average
stay was 8 days, which accounted for 4% of the hospital bed
capacity (Nainggolan, 2004). Another prospective cohort
study was carried out to evaluate more than 1200 outpatient
prescriptions, survey patients, and conduct a chart review dur-
ing a 4-week period. The researchers discovered that 25% of
patients experienced an ADR with selective serotonin-reuptake
inhibitors, beta blockers, angiotensin-converting-enzyme
inhibitors, and nonsteroidal anti-inﬂammatory drug classes
being the most frequently implicated. The rate of ADRs has
approached 27 per 100 patients (Gandhi et al., 2005). ADR
reporting has yet to be developed adequately. The need for in-
creased awareness of the importance of ADR reporting is vital
in Malaysia (Aziz et al., 2007).
1.2. Data sources
Asystematic review of the literature between the period of 1991–
2012 was made based on PubMed, the Cochrane database of
systematic reviews, EMBASE and IDIS. The articles searched
for included original articles, WHO and FDA reports and insti-
tute of medicine reports. Keywords used are: medication error,
adverse drug reaction, iatrogenic disease, factors, ambulatory
care, primary healthcare, side effects, and treatment hazards.
Search is done regardless of the date of publications.
1.3. Factors affecting the occurrence of ADRs
Kitteringham et al. (1994) suggested that for most adverse reac-
tions, particularly the idiosyncratic drug reactions, predisposi-
tion seems to be multifactorial, involving not only defects at
multiple gene loci but also environmental factors such as con-
comitant infection or the use of other drugs for different dis-
eases. The majority of ADRs occur as a result of the extension
of the desired pharmacologic effects of a drug, often due to
the substantial variability in the pharmacokinetics and pharma-
codynamics seen among patients. Pharmacological, immuno-
logical, and genetic factors are involved in the pathogenesis of
ADRs. Factors that predispose to pharmacological ADRs in-
clude dose, drug formulation, pharmacokinetic or pharmacody-
namic abnormalities, and drug interactions. The metabolic
conversion of drugs to metabolite is now established as a
requirement for many idiosyncratic drug reactions (Masubuchi
et al., 2007). Increased levels of reactive drug metabolites, their
impaired detoxiﬁcation, or decreased cellular defense against
reactive drug products appears to be an important initiating fac-
tor (Guengerich and MacDonald, 2007). Immunological and
genetic factorsmay play a role in the reaction of the body toward
the drugs given. Torpet et al. (2004) suggested ethnic variations
also play an important role in the development of ADRs. Evans
(2005) found that some risk factors are consistent for all ADRs
and acrossmultiple therapeutic classes of drugs, while others are
class speciﬁc. High-risk agents should be closely monitored
based on patient characteristics (gender, age, weight, creatinine
clearance, and number of comorbidities) and drug administra-
tion (dosage, administration route, number of concomitant
drugs). Factors which might increase the possibility of the
occurrence of ADRs include; extremes of age, gender, multiple
drugs, disease state, past history of ADR or allergy, geneticfactors, large doses and many other factors. Discontinuation
of the drugs or changing doses may be an important factor in
developing ADRs to certain drugs in certain populations espe-
cially the elderly. Agency for Healthcare Research (2001) sug-
gested another potential cause of ADRs can stem from the
clinician’s reluctance to treat with adequate doses of a drug
for fear of causing drug toxicity. ADRsmay be caused by errors
in manufacturing, supplying, prescribing, giving, or taking
drugs. Eighteen percent of drugs related to ADRs in the Har-
vardmedical practice study were judged to be due to negligence,
deﬁned as failure to meet the standard of care reasonably ex-
pected of a physician qualiﬁed to take care of the patient in ques-
tion (Leape et al., 1991). Bates et al. (2003) suggested ADRs
occurred frequently in the peridischarge period, andmany could
potentially have been prevented or ameliorated with simple
strategies. Factors affecting the occurrence of ADRs are subdi-
vided into ﬁve groups; Patient related factors, Social factors,
Drug related factors, Disease related factors and ADR related
factors.
2. Patient related factors
2.1. Age
All drugs can produce ADRs, but not all patients develop the
same level and type of ADRs. Age is a very important factor
which affects the occurrence of ADRs. Elderly patients with
multiple medical problems who are taking multiple drugs,
those who have a history of ADRs, and those with a reduced
capacity to eliminate drugs are at high risk for ADRs. A study
by Debellis et al. (2003) about the incidence and preventability
of ADRs among older persons in the ambulatory setting con-
cluded that ADRs are common and often preventable among
older persons in the ambulatory clinical setting. More serious
ADRs are more likely to be preventable. Prevention strategies
should target the prescribing and monitoring stages of phar-
maceutical care. Interventions focused on improving patient
adherence with prescribed regimens and monitoring of pre-
scribed drugs. Elderly and pediatric patients are particularly
vulnerable to ADRs because drugs are less likely to be studied
extensively in these extremes of age, and drug absorption and
metabolism are more variable and less predictable in both of
these groups. Efforts are needed to predict and prevent the
occurrence of ADRs in children (Bates et al., 2001). Infants
and very young children are at high risk of ADRs because their
capacity to metabolize the drug is not fully evaluated. The fol-
lowing are some factors that might affect the development of
ADRs in neonates (Clavenna and Bonati, 2008):
1. Neonates have immature renal tubular function when they
are below the age of 8 weeks, avoiding digoxin, aminogly-
cosides, ACE inhibitors, NSAIDs is a must (De-gregori
et al., 2009).
2. Physiologic hypoalbuminemia in neonates affects drug dos-
ing. Caution is recommended when dealing with high pro-
tein binding drugs such as NSAIDs (Anderson and Lynn,
2009).
3. Neonates, have low body fat; they might be affected by fat
soluble drugs (Iba´n˜ez et al., 2009).
4. Increased anesthetic effects due to immature blood brain
barrier at <8 weeks of age (Schoderboeck et al., 2009).
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ance and immature baroreceptors (Pellicer et al., 2009).
Older people are at high risk of developing an ADR for sev-
eral reasons. They are likely to have many health problems and
thus take several prescriptions and over the counter drugs. As
people get older, the liver loses the ability to metabolize drugs
(Budnitz et al., 2007). Also, older people are more than twice
as susceptible to ADRs as younger people (Hajar, 2003). As
people age, the amount of water in the body decreases and
the amount of fat tissue relative to water, increases. Thus, in
older people, drugs that dissolve in water reach higher concen-
trations because there is less water to dilute them, and drugs
that dissolve in fat accumulate more because there is relatively
more fat tissue to store them. Also, as people age, the kidneys
are less able to excrete drugs into the urine, and the liver is less
able to metabolize many drugs. Jimmy and Padma (2006) in
their study concluded that the incidence of ADRs among el-
derly adults and older adults was signiﬁcantly higher than
other age groups. They also elaborated that the type of
ADR is different among age groups, type A reactions were
more common among elderly adults (85.9%) and type B reac-
tions were more common in adults (35%) compared to other
age groups. Because of all age-related changes, many drugs
tend to stay in an older person’s body much longer than they
would in a younger person’s body, prolonging the drug’s effect
and increasing the risk of side effects (Klotz, 2009).2.2. Gender
The biological differences of males and females affect the ac-
tion of many drugs. The anatomical and physiological differ-
ences are body weight, body composition, gastrointestinal
tract factors, liver metabolism, and renal function. Women
in comparison to men have lower bodyweight and organ size,
more body fat, different gastric motility and lower glomerular
ﬁltration rate. These differences can affect the way the body
deals with drugs by altering the pharmacokinetics and phar-
macodynamics of the drugs including drug absorption, distri-
bution, metabolism and elimination. Gender plays a role in
the effect on ADRs. A study of sex differences in ADRs to
antiretroviral drugs indicates potential sex differences in the
frequency and severity of ADRs to antiretroviral drugs (Ofo-
tokun and Pomeroy, 2003). Hepatic enzyme CYP3A4 is more
active in females than males which lead to different effects on
drug metabolism (El-Eraky and Thomas, 2003). They also sug-
gested that women are more prone than men to develop tor-
sade de pointes ventricular tachycardia during the
administration of drugs that prolong cardiac repolarization.
Women restrict their activity because of acute and chronic
health problems approximately 25% more days per year than
do men, spending approximately 40% more days in bed each
year than men (Legato, 1998). Women aged 17–44 years have
twice as many physician visits and hospital stays as men. When
reproductive and other sex-speciﬁc conditions are excluded,
the difference in hospital stay virtually disappears, but the dif-
ference in ambulatory care is still approximately 30%. After
the age of 45, when all sex-speciﬁc conditions are excluded,
women continue to have approximately 10–20% more physi-
cian visits, with men having a greater frequency of hospitaliza-
tion (Ensom, 2000).In a north Indian study by Singh et al. (1998) on angioten-
sin converting enzyme inhibitors and cough, females had a
higher incidence of cough compared to males (37.9% vs.
15.5%). In Chinese populations, the metabolism of midazolam
in women is more than in men due to the activity of CYP3A4
(Labbe´ et al., 2000). Moreover, the pharmacodynamic differ-
ences between men and women are particularly seen with car-
diac and psychotropic drugs. Chlorpromazine and ﬂuspirilene
seem to be more effective in women than in men for the same
dosage and plasma concentration (Bing et al., 2003). Some
drugs affect one sex without the other, e.g. colchicine which
is used for the treatment of many diseases including Familial
Mediterranean fever might affect fertility in males but not in
females (Sternberg and Hubley, 2004). On the other hand, he-
patic drug reactions are more common in females. It was esti-
mated that the female gender is a risk factor for hepatotoxicity
more than men (Rajani et al., 2004). Gender differences refer
not only to biologic differences but to physiologic, social,
behavioral, and cultural differences as well. Results of various
animal studies illustrated the fact that a signiﬁcant difference
in drug metabolism and elimination due to gender difference
provide an impetus for sex based research in humans (Meyer
et al., 2009). Recent advances in the characterization of speciﬁc
isoenzymes of drug metabolism paved the way for preliminary
identiﬁcation of the enzyme system affected by sex. Limited
current studies showed apparent CYT P450 (CYP 3A4) activ-
ity higher in females than in males while other enzymes are in-
creased in males (Waxman and Holloway, 2009). Men and
woman show different pharmacodynamic responses to various
drugs which may lead to different therapeutic responses. Fe-
male speciﬁc issues such as pregnancy, menopause and men-
struation may have profound drug effects in humans
(Mitchell et al., 2009). A few clinically signiﬁcant ones like in-
creased elimination of anti-epileptics decreasing their efﬁcacy
in pregnancy, oral contraceptives interfering with metabolism
of many drugs and conversely certain drugs can impair contra-
ceptive efﬁcacy (Dorothy et al., 2008). Moreover, the most
pronounced differences between women and men (54% vs.
46%, respectively) were seen in a study about the incidence
of ADRs caused by cardiovascular medications; low-ceiling
diuretics caused a relative risk of 4.02, cardiotonic glycosides
caused a relative risk of 2.38, high-ceiling diuretics caused a
relative risk of 2.10 and coronary vasodilators caused a relative
risk of 0.77 (Rodenburg et al., 2012).
One of the most consistent observations in health research is
that women report symptoms of physical illness at higher rates
thanmen. Still unresolved is whether this is due to clinical differ-
ences inmorbidity or disease severity, or to differences in the fol-
lowing: illness behavior – women are more likely than men to
interpret discomfort as symptoms; symptom perception – wo-
men’s attentiveness to body discomfort increases their percep-
tion of symptoms and evaluation of those symptoms as illness;
or symptom reporting – women may be more likely to recall
and report symptoms (Verbrugge, 1985; Ahmed et al., 2009).
2.3. Maternity status
Pregnancy has an impact on drug treatment. Not only are wo-
men affected by the drug, but the fetus will also be exposed to
ADRs of the drug. There are certain physiologic changes that
occur during pregnancy which might affect drug pharmacoki-
netics and pharmacodynamics, these changes are; total blood
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volume increase during the 2nd and 3rd trimester which leads
to decreased plasma concentration of iron and some drugs, re-
nal function improves with a renal plasma ﬂow increment of
30% and GFR increases 50%, serum protein 1–1.5 lower; thus
renally excreted drugs would have an increased rate of excre-
tion, cardiovascular changes are noted by an increase in car-
diac output of about 32% due to an increased heart rate
(10–15 bpm) and increased stroke volume, blood pressure is
relatively constant. Motility, acidity and tone of GIT are de-
creased during pregnancy and this might interfere with drug
absorption or excretion and ﬁnally drug metabolism may be
affected at certain stages of pregnancy (Duncombe et al.,
2008). Drugs during pregnancy might affect either the mother
or the embryo or both. The impact of drugs on fetal organo-
genesis is crucial because it might lead to teratogenicity and
Dysmorphogenesis (Pack et al., 2009). Many drugs for exam-
ple, antihypertensive drugs such as angiotensin-converting en-
zyme (ACE) inhibitors and angiotensin II receptor blockers
pose a risk to the health and normal development of a fetus
(Alomar and Strauch, 2010).
2.4. Fetal development
The fetus, which is exposed to any drugs circulating in maternal
blood, is very sensitive to drug effects because it is small, has few
plasma proteins that can bind drug molecules and has a weak
capacity for metabolizing and excreting drugs. Once drug mol-
ecules reach the fetus, they may cause teratogenicity (anatomic
malformations) or other ADRs (Brundage, 2002). Gestational
age is subdivided into three trimesters; ﬁrst, second and third tri-
mester. The effect of drugs on each trimester is different depend-
ing on the degree of fetal development. Drug teratogenicity is
most likely to occur when drugs are taken during the ﬁrst trimes-
ter of pregnancy, when fetal organs are formed (Holmes et al.,
2001). For drugs taken during the second and third trimesters,
ADRs are usually manifested in the neonate (birth to 1 month)
or infant (1 month to 1 year) as growth retardation, respiratory
problems, infection, or bleeding. Overall, effects are determined
mainly by the type and amount of drugs, the duration of expo-
sure, and the level of fetal growth and development when ex-
posed to the drugs. Both therapeutic and nontherapeutic
drugs may affect the fetus (Meloni et al., 2009).
2.5. Creatinine clearance category
Creatinine clearance reﬂects the function of the kidneys which
are responsible for the excretion of many drugs. Any change in
the renal proﬁle might increase drug toxicity or decrease ther-
apeutic effect. Kidney disease affects drug clearance and
metabolism. Venitz (2000) concluded that chronic renal failure
affects both renally excreted drugs and also drugs metabolized
by the liver through the effect of uremia caused by renal fail-
ure. This in turn may affect the disposition of a highly metab-
olized drug by changes in plasma protein binding and hepatic
metabolism. Sun et al. (2006) stated that alterations of drug
transporters, as well as metabolic enzymes, in patients with re-
nal failure can be responsible for reduced drug clearance. This
reduced metabolic enzyme activity can affect the clearance of
the drug (Naud et al., 2008). The effect of renal diseases on
non renal drug excretion leads to any disease accompaniedwith renal insufﬁciency being affected by this insufﬁciency
and increases the possibility of the appearance of ADRs in that
patient.
2.6. Allergy
Drug independent cross-reactive antigens can induce sensitiza-
tions, which can manifest as a drug allergy. The existence of
such cross-reactivity is supported by medical literature (Chung
et al., 2008). After primary sensitization to a causative drug, a
second exposure causes affected T cells and antibodies to enter
the elicitation phase, corresponding to the type I to IV immune
reactions (Gell and Coombs Classiﬁcation). Most of the drug
allergies observed are type I or IV reactions; type II and III
reactions are only encountered infrequently (Harboe et al.,
2007). The formation of immune complexes, a common event
in a normal immune response, usually occurs without symp-
toms. Rarely, immune complexes bind to endothelial cells
and lead to immune complex deposition with complement acti-
vation in small blood vessels (Schmid et al., 2006). The clinical
symptoms of a type III reaction include serum sickness (e.g., b-
lactams), mediation-induced lupus erythematosus (e.g., quini-
dine), and vasculitis (e.g., minocycline) (Benseler et al., 2007).
T-cell-mediated drug hypersensitivity may have a variety of
clinical manifestations, ranging from involvement of the skin
alone to fulminant systemic diseases. Frequently, the drugs in-
volved are sulfa antibiotics and b-lactams (Ebert et al., 2005).
2.7. Body weight and fat distribution
In the body, drugs are distributed to and from the blood and
various tissues of the body (for example, fat, muscle, and brain
tissue). After a drug is absorbed into the bloodstream, it rap-
idly circulates through the body. As the blood recirculates,
the drug moves from the bloodstream into the body’s tissues.
Once absorbed, most drugs do not spread evenly throughout
the body. Some drugs dissolve in water (water-soluble drugs),
such as the antihypertensive drug atenolol. Some drugs tend to
stay within the blood and the ﬂuid that surrounds cells (inter-
stitial space). Drugs that dissolve in fat (fat-soluble drugs),
such as the anesthetic drug halothane, tend to concentrate in
fatty tissues. Other drugs concentrate mainly in only one small
part of the body (for example, iodine concentrates mainly in
the thyroid gland), because tissues have a special attraction
for (afﬁnity) and ability to retain the drug. Drugs penetrate dif-
ferent tissues at different speeds, depending on the drug’s abil-
ity to cross membranes. For example, the anesthetic
thiopental, a highly fat-soluble drug, rapidly enters the brain,
but the antibiotic penicillin, a water-soluble drug, does not.
In general, fat-soluble drugs can cross cell membranes more
quickly than water-soluble drugs. For some drugs, transport
mechanisms aid movement into or out of the tissues (Anderson
and Holford, 2008). Some drugs leave the bloodstream very
slowly, because they bind tightly to proteins circulating in
the blood. Others quickly leave the bloodstream and enter
other tissues, because they are less tightly bound to blood pro-
teins. Some or virtually all molecules of a drug in the blood
may be bound to blood proteins. The protein-bound part is
generally inactive. As the unbound drug is distributed to tis-
sues and its level in the bloodstream decreases, blood proteins
gradually release the drug bound to them. Thus, the bound
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(Standing et al., 2010). Some drugs accumulate in certain tis-
sues, which can also act as reservoirs of the extra drug. These
tissues slowly release the drug into the bloodstream, keeping
blood levels of the drug from decreasing rapidly and thereby
prolonging the effect of the drug. Some drugs, such as those
that accumulate in fatty tissues, leave the tissues so slowly that
they circulate in the bloodstream for days after a person has
stopped taking the drug (Zhao et al., 2009). Distribution of
a given drug may also vary from person to person. For in-
stance, obese people may store large amounts of fat-soluble
drug, whereas very thin people may store relatively little. Older
people, even when thin, may store large amounts of fat-soluble
drugs because the proportion of body fat increases with aging
(Rhodin et al., 2009).
3. Social factors
3.1. Alcohol drinking
Alcohol affects the metabolism of many drugs and it facilitates
the development of ADRs. Alcohol drug interaction refers to
the possibility that alcohol may change the intensity of the
development of ADRs making it more toxic or harmful to
the patient either in a pharmacokinetic or pharmacodynamic
manner (Bruce et al., 2008). Taking alcohol with certain drugs
can cause many ADRs like nausea, vomiting, headaches,
drowsiness, fainting, loss of coordination, hypotension and
many other ADRs (Krupski et al., 2009). Internal bleeding
may occur due to severe ulceration if alcohol is taken with
NSAIDs by a patient having peptic ulcer or ex-peptic ulcer
or gastritis (Kim et al., 2009). Chronic alcohol consumption
activates enzymes which transform some drugs into toxic
chemicals that can damage the liver and other body organs.
Alcohol can also magnify the inhibitory effects of sedatives
and narcotics at their site of action in the brain. Alcohol might
affect the functionality of the liver causing liver cirrhosis and
liver hepatitis which in turn affect the ability of this organ to
metabolize drugs especially drugs metabolized by the liver
and drugs which have ﬁrst pass metabolism. E.g. the toxicity
of beta blockers increases with liver problems (Reuben,
2006). This will lead to drug interactions, because of that phy-
sicians and pharmacists must warn patients about the health
hazards that might be caused by alcohol drug interaction
(Brown et al., 2007). Alcohol drug interaction may be more
harmful when elderly patients mix them together, as age and
alcohol lead to many health problems (Pringle et al., 2005).
3.2. Race and ethnicity factors
Evidences suggest that ethnicity exerts a substantial inﬂuence
on drug response and action. Drug action varies greatly be-
tween individuals. Ethnic background is controlled by genetic
factors, which makes the inter-individual differences due to
polymorphisms in genes encoding drug metabolizing enzymes,
drug transporters, and receptors (Sexton et al., 2000). Recent
development suggests that ADRs may be avoided by individu-
alizing the therapeutic plan according to genetics (Meigs et al.,
2008). David et al., 2001) suggested genetics play a crucial part
in the willingness of some patients to develop ADR for a spe-
ciﬁc drug over others. A study on epidemiological risk factorsfor hypersensitivity reactions to abacavir found the Caucasian
race as a risk factor for ADRs (Lyssenko et al., 2008). In a re-
cent cohort study Morimoto et al. (2004) evaluated risk factors
for ADRs associated with angiotensin-converting enzyme
(ACE) inhibitors involving 2225 people of whom 19% had
to discontinue therapy due to ADRs, African Americans were
found to be more susceptible to developing ACE-related angi-
oedema than other ethnic groups. Ethnicity is an important
demographic variable contributing to interindividual variabil-
ity in medication metabolism and response. Some studies are
discussing the issue that genetic factors can determine individ-
ual susceptibility to both dose-dependent and dose-indepen-
dent ADRs. Determinants of susceptibility include kinetic
factors, such as gene polymorphisms in cytochrome P450 en-
zymes, and dynamic factors, such as polymorphisms in drug
targets (Cornelis et al., 2009). The relative importance of these
factors will depend on the nature of the ADRs; however, it is
likely that more than one gene will be involved in most in-
stances (Pirmohamed and Park, 2001). Different ethnic groups
have different risks for important ADRs to cardiovascular
drugs. Ethnic groups may therefore be one determinant of
harm of a given treatment in the individual patient, either be-
cause it acts as a surrogate measure of genetic makeup or be-
cause cultural factors alter the risk. Black patients had a
relative risk of angioedema of 3.0 compared with non-black
patients, and the risk of intracranial hemorrhage was higher
in black patients than non-black patients (McDowell et al.,
2006). These ﬁndings may help healthcare providers present
more accurate and relevant data to their patients when pre-
scribing cardiovascular therapy. The problem with trials is that
the groups of people in trials are not necessary representatives
of the general population and if they are, their background
might not be speciﬁed. It is also documented that the risk of
angioedema with blood pressure lowering drugs was three
times greater in black patients than non-black patients (Grouz-
mann et al., 2009). The risk of cough was also nearly three
times higher in East Asian patients compared with white pa-
tients (Hoffmann and Bier, 2007). For thrombolytic therapy,
the risk of bleeding increased 1.5-fold in black patients com-
pared with non-black patients (Mahoney and Devaiah,
2008). Another study shows that 17% of black patients vs.
11% of non-black patients experienced moderate to severe
bleeding following thrombolytic therapy; these data come
from the global utilization of streptokinase and tissue plasmin-
ogen activator for occluded coronary arteries (Coleman et al.,
2006). The same study concluded that there was signiﬁcantly
more depression from hydrochlorothiazide (HCTZ) for black
patients compared with white patients. Non-whites (namely,
black, hispanic, or other) had a higher risk of hospital admis-
sion from bleeding after oral anticoagulation for deep vein
thrombosis (Kracoff, 2005). Of 58 patients treated with ibuti-
lide fumarate injection for the recent onset of atrial ﬁbrillation
or atrial ﬂutter, 3 of 20 (15%) black patients, compared with 1
of 38 (2.63%) white patients, developed Torsade de Pointes
after treatment (Regitz-Zagrosek, 2006). Human leukocyte
Antigen (HLA) genotype is an essential predictor of the sus-
ceptibility of drug-induced liver toxicity. HLA genotype is
not the main cause of liver toxicity, there are other genotypes
like SLCO1B1 which lead to simvastatin myotoxicity (Daly,
2012). Ten percent of the patients who take Carbamazepine
suffer from cutaneous adverse reactions. These ADRs have
been attributed to the human leukocyte antigen (HLA)
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ing HLA-B 1502 in Asians was associated with a pooled odds
ratio (OR) of 113.4 for Carbamazepine-induced Stevens–John-
son syndrome and toxic epidermal necrolysis (Marson et al.,
2012). Another recent study showed that patients with ADRs
had a higher frequency of CYP1A2 low activity allele combi-
nations (8/12; 67%) and lower CYP1A2-mRNA levels than
patients without ADRs (6/22; 27%, P= 0.019) (Ferrari,
2012). In Parkinson’s disease patients with UDP-glucuronosyl-
transferase 1A9 genotypes are prone to ADRs and to catechol-
O-methyltransferase inhibitors (Ferrari, 2012).
3.3. Smoking
Smoking is one of the risk factors of many diseases like peptic
ulcer, cancer and cardiovascular diseases (Woo et al., 2009). It
also affects the metabolic process by affecting liver enzymes act-
ing as a potent inducer of the hepatic cytochrome P-450 (CYP)
isoenzymes 1A1, 1A2, and, possibly, 2E1 (Tomlinson et al.,
2005).Many drugs are substrates for hepatic CYP1A2, and their
metabolism can be induced in smokers, resulting in a clinically
signiﬁcant decrease in pharmacologic effects (Faber and Fuhr,
2005). These drug interactions are not caused by nicotine, the
cause is tobacco. Because it stimulates the sympathetic nervous
system, nicotine can counter the pharmacologic actions of some
drugs (Hukkanen et al., 2005). More research ﬁndings world-
wide revealed the smoking-drug interaction, and theophylline,
ﬂecainide, insulin, oral contraceptives, beta-blockers, thiothix-
ene and H2 blockers are medicines whose therapeutic responses
can be affected by smoking (Himmelmann et al., 2003).One clin-
ical study showed that on average insulin-dependent diabetic
smokers needed 15–20% more insulin than non-smokers, and
up to 30%more if they smoked heavily (Kroon, 2007). Cigarette
smoking increases the rate of heparin clearance, possibly be-
cause of the smoking-related activation of thrombosis with in-
creases of heparin binding to antithrombin III (Faber and
Fuhr, 2005). Cutaneous vasoconstriction by nicotine may de-
crease the rate of insulin absorption after subcutaneous admin-
istration (Schwing et al., 1999). Cigarette smoking also reduces
the effect of beta blockers on blood pressure and heart rate (Ze-
vin and Benowitz, 1999).
4. Drug related factors
4.1. Polypharmacy
Taking several drugs, whether prescription or over-the-coun-
ter, contributes to the risk of having an ADR. The number
and severity of ADRs increases disproportionately as the num-
ber of drugs taken increases. Many deﬁnitions are applied for
polypharmacy. It is different from scholar to scholar but the
basic concept of taking more medications at the same time
than are clinically appropriate remains constant (Bushardt
et al., 2008). It implies to the prescription of too many medica-
tions for a particular patient, with a possibility of increased
risk of ADRs. The more the medications that are prescribed
the more the possibility of polypharmacy, this does not neces-
sarily mean however that patients should not take many med-
ications (Rambhade et al., 2012).
Polypharmacy is a result of many conditions; patients
might suffer from more than one disease especially amongthe elderly. Patients might seek more than one prescriber at
the same time for different diseases or acute or chronic condi-
tions. ADRs may occur due to drug interaction, synergism,
duplication, additive effect, discontinuation of therapy, chang-
ing the dose to save money, skipping some medications and
physiological antagonism. One important reason for the devel-
opment of ADRs from polypharmacy is the inability of some
patients especially the elderly to keep track of using their med-
ications regardless of how well the medications may work if gi-
ven alone. If the patients are not strict enough to take the
medications as prescribed, then they will separate from treat-
ment and not take the medication properly. Economic value
of the medications may lead to skipping some of them which
in turn causes shortage of treatment and the development of
adverse events. Prescribing cascade is also a result of polyphar-
macy in which certain drugs are used to treat the adverse effect
of other drugs. This will potentially lead to an endless line of
medications used by the patient. It is possible that symptoms
and signs of polypharmacy could be overlooked by confusing
them with symptoms of aging or the disease itself. This in turn
will result in more medications being taken by the patients.
Constipation, diarrhea, tiredness, weakness, skin rashes, falls,
anxiety and many other symptoms could be caused by both
diseases and polypharmacy. A study among 65 year old pa-
tients and older in the United States of America found that
in more than 40% of the patients involved in the study there
was evidence of incorrect medication use, overuse and under-
use for those treated by more than ﬁve medications (Steinman
et al., 2006). The risk of dementia increases steadily with the
number of medications used and age in older people as de-
scribed in a study in Taiwan (Lai et al., 2012). ‘In another
study of the frequency of polypharmacy with three or more
medications at hospital discharge for bipolar disorders or uni-
polar depression, polypharmacy increased from 3.3% of pa-
tients (1974–1979), to 9.3% (1980–1984), to 34% (1985–
1989), and to 43.8% (1990–1995)’ (Hoffman et al., 2011). An-
other study regarding the development of Acute Renal Failure
(ARF) as a result of polypharmacy indicated that ‘relative to
patients who received polypharmacy for less than 30 days,
those who received polypharmacy for 31–90, 91–180 and over
181 days had odds ratios of developing ARF of 1.33
(p< 0.001), 1.65 (p< 0.001) and 1.74 (p< 0.001), respec-
tively (Chang et al., 2012)’.
Drug interactions play a very important role in the develop-
ment of polypharmacy and can be deﬁned as the modulation
of the pharmacologic activity of one drug by the prior or con-
comitant administration of another drug. It is also deﬁned as
an interaction which occurs when the effects of one drug are
changed by the presence of another drug (Kaufman et al.,
2002). The causes and signiﬁcance of drug interactions are
multifaceted and include drug dose, serum drug level, route
of administration, drug metabolism, duration of therapy,
and patient factors, such as age, gender, weight and genetic
predisposition (Heuberger, 2012). Drug interactions are often
classiﬁed as either pharmacodynamic or pharmacokinetic
interactions. Pharmacodynamic interactions include those that
result in additive or antagonistic pharmacological effects
(Wildinson et al., 2010). Pharmacokinetic interactions involve
induction or inhibition of metabolizing enzymes in the liver or
elsewhere, displacement of drug from plasma protein binding
sites, alterations in gastrointestinal absorption, or competition
for active renal secretion. The frequency and prevalence of
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drugs and the complexity of the regimens (Wildinson et al.,
2010). The prevalence is also dependent upon other variables,
such as patient adherence, hydration and nutritional status,
degree of renal or hepatic impairment, smoking and alcohol
use, genetics and drug dosing. Additionally, some patients
may exhibit evidence of a particular drug interaction, while
others with the same drug combination do not (Obreli-Neto
et al., 2012). The addition of nonprescription medications
plays a very important role in causing ADRs. Some studies
indicate that patients aged >65 years use on average 2–6 pre-
scribed medications, and 1–3.4 nonprescribed medications
(Routledge et al., 2003). It is a well established fact that non
prescription medications are most commonly used among the
geriatric population (Prybys et al., 2002). A drug combination
may sometimes cause synergistic toxicity, which is greater than
the sum of the risks of toxicity of either agent used alone
(Harugeri et al., 2011). Patients concurrently receiving cortico-
steroids and NSAIDs had a risk of peptic ulcer disease that
was 15 times greater than that of nonusers of either drug
(Routledge et al., 2003). The concurrent use of antidepressants,
hypnotics, antiepileptics and antihistamines may lead to more
drowsiness (Nidhi, 2012). Both vancomycin and narcotics in-
duce dose-dependent skin reactions and synergize to cause ad-
verse reactions (Yeon et al., 2011). Prescribing cascade occurs
when patients take a medication and suffer from some adverse
drug reactions that are misdiagnosed by the physicians as
symptoms of a disease, requiring more medication. This condi-
tion may lead to either worsening of the ADR or putting pa-
tients at risk of new ADRs. Antihypertensives, Sedatives,
Opioids, NSAIDs, Antiepileptics, Antibiotics and herbal med-
ications are some of the most frequently prescribed drugs. The
cascades include the use of prochlorperazine to prevent drug-
induced dizziness, antihypertensives to treat NSAID-induced
hypertension and levodopa to manage metoclopramide-in-
duced movement disorder (Kalisch et al., 2011). Prochlorpera-
zine for instance may cause postural hypotension which may
exacerbate any hypotensive effect of antihypertensive drugs.
This cascade might be the cause of hip fracture following the
use of prochlorperazine (Caughey et al., 2010). ACEIs induced
cough may be misinterpreted as a chest infection and given
antibiotics and cough suppressant. Thiazide diuretics may
cause hyperuricemia which leads to prescribing colchicines
which in turn may cause diarrhea (Rochon and Gurwitz,
1997). Erythromycin may cause arrhythmia and be misinter-
preted as a disease and given antiarrhythmics (Corrao et al.,
2005). Antiepileptics may cause a rash which leads to cortico-
steroid use (Tsiropoulos et al., 2009). Using therapeutic equiv-
alents to treat the same illness is considered one of the causes
of ADRs, two analgesics, antihistamine with other sedative
drugs or two antihypertensives are some examples of using
two medications which exhibit the same action. Lack of coor-
dination between physicians, pharmacists and patients can in
turn lead to redundancy, using the same medications under
different brand names. This will increase the risk of ADRs.
Finally; some studies indicate that polypharmacy might affect
the nutritional status of patients which leads to malnutrition
(Zdenek et al., 2013) which is more pronounced among the
older population. Polypharmacy should be looked at seriously
in order to prevent potential ADRs which affect patient health
status, compliance and therapeutic outcomes.4.2. Drug dose and frequency
Drug dosing affects the development of ADRs in many ways;
e.g. some drugs need to be given in the morning and others in
the evening, some at bedtime. Taking Bisphosphonates at bed
time may lead to esophagitis, the antiplatelet effect of aspirin
when taking in the evening is more potent that in the morning
(Hermida et al., 2005). Dosing needs to be considered as a fac-
tor which might have some effect on the development of ADRs.
5. Disease related factors (accompanied diseases)
Concomitant patient’s disease may also inﬂuence susceptibility
to ADRs. For example; increases of the frequency of idiosyn-
cratic toxicity with anti-infective drugs such as trimethom-
prim-sulphamethoxazole (Hanses et al., 2009). Multiple
diseases make patients more vulnerable to ADRs due to the
presence of many diseases and the use of many drugs. If hyper-
tension is accompanied with other diseases, these diseases
might have an impact on the response of the body to antihy-
pertensive drugs since the metabolic processes of the body will
be affected negatively. In patients with renal failure, the effect
of drugs on the kidneys is lessened because of the loss of the
site of action for these drugs. This leads to increasing the dose
which in turn leads to more ADRs. The same issue occurs in
patients with peptic ulcer disease, many drugs including NSA-
IDS when prescribed, may lead to serious medical problems
(Daneshtalab et al., 2004). Multiple diseases are a very impor-
tant factor which causes drug-disease interactions and ADRs.
Drugs that are helpful in one disease are harmful in another.
For example, some beta-blockers taken for heart disease or
high blood pressure can worsen asthma and make it hard for
people with diabetes to tell when their blood sugar is too
low. Some drugs taken to treat a cold may worsen glaucoma.
Diabetes, high or low blood pressure, an ulcer, glaucoma, an
enlarged prostate, poor bladder control, and insomnia are par-
ticularly important, because people with such diseases are
more likely to have drug-disease interactions (Kurnik et al.,
2004). Certain drugs have the capability to exacerbate acute
and/or chronic disorders. These drugs can also blunt the typi-
cal signs and symptoms of a hypoglycemic reaction in diabetic
patients and alter insulin utilization in the body (Peng et al.,
2002). These drugs and calcium channel blockers, particularly
verapamil, have negative inotropic and negative chronotropic
effects on the heart and can exacerbate diseases such as conges-
tive heart failure (Ariyo et al., 2000). Prednisone can aggravate
congestive heart failure and cause ﬂuid retention. Because
some of these interactions may have an insidious onset, careful
and close medical attention is mandatory (Boer et al., 2003).
AIDS for instance worsen ADRs, the incidence of Stevens–
Johnson syndrome (SJS) and toxic epidermal necrolysis
(TEN) has been reported to be higher among those particular
patients. A study shows that one of the medications taken
among patients who developed TEN AND SJS is trimetho-
prim/sulfamethoxazole (Mittman et al., 2012). According to
a recent study of a multivariate logistic regression indicated
that a T CD4+ count of <200 cells/mm3 increased the risk
of hepatotoxicity by a factor of 1.233 (p< 0.001) and that
coinfection with hepatitis B or C virus increased this risk by
a factor of 18.187 (p= 0.029) (Lima and Melo, 2012).
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Different factors affect the development of ADRs in different
degrees, some of these factors have a direct effect on ADRs,
others are insidious. Serious attention to these factors will re-
sult in preventing or reducing the occurrence of unwanted drug
actions which could have been avoided if health care providers
spent enough time to pinpoint these problems. Health educa-
tion, counseling and reconciliation are tools that must be uti-
lized by pharmacists. Information technology should also be
part of the medication decision making process which provides
health professionals with up to date knowledge of drug-dosing,
interaction, ADRs and other important information needed to
use medication in the optimum manner. The elderly should
also be the focus of the pharmacist, because they form the
majority of those who uses polypharmacy. Finally; for each
beneﬁt to come out of a medication there is always a possibility
for some risks; beneﬁts should always outweight risks for the
purpose of providing the best treatment with the least number
of medications at the most economic price.
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